News articles about Endocyte (NASDAQ:ECYT) have been trending somewhat positive on Wednesday, Accern reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Endocyte earned a daily sentiment score of 0.03 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.7279004186912 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:

How to Become a New Pot Stock Millionaire

Endocyte (ECYT) opened at $10.82 on Wednesday. The firm has a market capitalization of $426.93, a price-to-earnings ratio of -8.45 and a beta of 1.02. Endocyte has a 12 month low of $1.17 and a 12 month high of $11.54.

Endocyte (NASDAQ:ECYT) last posted its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.02). The company had revenue of $0.01 million during the quarter. Endocyte had a negative net margin of 78,662.86% and a negative return on equity of 40.33%. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.26) earnings per share. equities research analysts anticipate that Endocyte will post -0.87 earnings per share for the current year.

A number of brokerages have commented on ECYT. Wells Fargo & Co began coverage on Endocyte in a research report on Friday, March 9th. They issued an “outperform” rating on the stock. Zacks Investment Research lowered Endocyte from a “hold” rating to a “sell” rating in a research report on Thursday, February 15th. BidaskClub upgraded Endocyte from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Cowen upgraded Endocyte from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 27th. Finally, ValuEngine lowered Endocyte from a “sell” rating to a “strong sell” rating in a research report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Endocyte has a consensus rating of “Buy” and a consensus target price of $7.00.

In related news, insider Philip S. Low sold 50,511 shares of the firm’s stock in a transaction on Thursday, December 28th. The stock was sold at an average price of $4.41, for a total transaction of $222,753.51. Following the sale, the insider now owns 354,050 shares of the company’s stock, valued at approximately $1,561,360.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Christopher P. Leamon sold 5,036 shares of the firm’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $9.07, for a total value of $45,676.52. Following the sale, the vice president now directly owns 143,470 shares in the company, valued at approximately $1,301,272.90. The disclosure for this sale can be found here. In the last three months, insiders sold 106,058 shares of company stock worth $491,184. 14.86% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Endocyte (ECYT) Receives Daily Coverage Optimism Score of 0.03” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at

Endocyte Company Profile

Endocyte Inc (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Insider Buying and Selling by Quarter for Endocyte (NASDAQ:ECYT)

Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with's FREE daily email newsletter.